Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.

Míreanna comhchosúla

• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
  de réir: Kahn, SE, et al.
  Foilsithe / Cruthaithe: (2006)
• Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT.
  de réir: Kahn, SE, et al.
  Foilsithe / Cruthaithe: (2011)
• Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
  de réir: Zinman, B, et al.
  Foilsithe / Cruthaithe: (2010)
• Greater reductions in C-reactive protein with rosiglitazone than with glyburide or metformin despite greater weight gain
  de réir: Haffner, S, et al.
  Foilsithe / Cruthaithe: (2007)
• ADOPT: The effectiveness of metformin versus glyburide in type 2 diabetes
  de réir: Herman, W, et al.
  Foilsithe / Cruthaithe: (2007)